Veeva Systems has been ranked No. 15 on Fortune’s annual “100 Fastest-Growing Companies” list, capping off what has been a successful and busy year for the healthcare software startup.
This is Veeva’s fourth year in a row to make the cut. Over the past three years, Fortune reported that the company has generated more than $1.2 billion in revenue and brought in $329 million in profits, bringing its total valuation to $3.2 billion.
Headquartered in Pleasanton, California, Veeva builds enterprise cloud technology that helps power some of the biggest names in the healthcare space, including Pfizer and Moderna. These companies use Veeva to manage data-heavy tasks, allowing them to get the critical products and services they provide out to the public faster.
Lately, Veeva has been focusing a lot of its attention on clinical trials, creating two new products — SiteVault and MyVeeva — to make the space more remote friendly, especially in the midst of the pandemic when in-person interactions need to be at a minimum. SiteVault automates the flow of all the information and documentation that gets produced in a clinical trial. Meanwhile, MyVeeva provides a space where clinical trial doctors, patients and research coordinators can communicate through audio and video, reducing the need for in-person visits.
To continue its work in the clinical trial space, Veeva announced in October it planned to hire 200 software developers over the next several months. Although the company is based in the Bay Area, it decided to do much of its recruiting in Boston, claiming the city is a “mecca for the biotech industry.”
Veeva has more than 4,000 employees, 100 of which are in Boston, and is hiring for more than 80 tech positions locally now.
Looking ahead, Fortune also seems to think Veeva has a lot of potential for growth, ranking it No. 2 on its “Future 50” list, which identifies companies with the best long-term growth potential.
“Every successful business starts with an act of imagination. But the most innovative companies are those that continually reimagine their potential — even if it means embracing radical shifts in strategy,” Fortune said. “The cloud computing revolution has at last come for life sciences, thanks to Veeva’s industry-targeted offerings.”
